Indirect Markers of Intestinal Damage in IgA Nephropathy.

Abstract

Presence of subclinical intestinal inflammation has repeatedly been shown in IgA nephropathy (IgAN) and the degree of histological inflammation has correlated with abnormal urinary findings. There is lack of noninvasive biomarkers evaluating the presence of subclinical intestinal damage in IgAN. We conducted this study hypothesizing that selected biomarkers regarded as indirect markers of intestinal damage could be elevated in IgAN. Eighty-five primary IgAN patients (median age 55 years, 54% men) participated in this single-centre study in Tampere, Finland. None had end-stage kidney disease or previously diagnosed enteropathies. Celiac disease (CeD) was excluded with serum transglutaminase 2 antibody (TG2Ab) and endomysial antibody (EmA) tests and inflammatory bowel disease (IBD) with fecal calprotectin. Intestinal damage was evaluated from sera with analyses of intestinal fatty-acid binding protein (I-FABP), soluble cluster of differentiation molecule 14 (sCD14) and lipopolysaccharide binding protein (LBP). Fourteen people suffering from dyspepsia and 15 healthy people served as controls. I-FABP levels among IgAN patients were higher than in the healthy controls (median 830 pg/ml vs. 289 pg/ml, p<0.001). Also, sCD14 was increased in IgAN patients compared to dyspepsia controls. Although TG2Ab levels were within the normal range among IgAN patients, they were higher than in the healthy controls (median 1.3 U/ml vs. 0.6 U/ml, p<0.001). Elevated serum levels of I-FABP were present in primary IgAN patients without known enteropathies. Serum I-FABP may indicate the presence of subclinical intestinal damage. These findings encourage further investigation into the role of the intestine in the pathophysiology of IgAN.